Company intelligence / Profile preview

Bond Avillion 2 Development LP

Ownership: Private
Development stage: Phase 3

Overview

Bond Avillion 2 Development LP has a 100% success rate in clinical trials reporting. The company has successfully developed Albuterol/Budesonide for asthma, which received FDA approval on January 10, 2023. They have also conducted a positive Phase 2 trial of Sonelokimab (M1095), an anti-IL-17 AF Nanobody, in chronic psoriasis.

Therapeutic areas: PulmonologyDermatologyRheumatology
Modalities: Small moleculesBiologics
Industry: Biotech

Drug pipeline

1 asset

PT027

Phase 3

Indications: Asthma

Partnerships

AstraZeneca PLCPearl Therapeutics Inc.MoonLake Immunotherapeutics

Beyond the preview

Go deeper on Bond Avillion 2 Development LP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bond Avillion 2 Development LP.

Explore the full profile